Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.
Aim(s): To evaluate the effectiveness of lanreotide in pts with early-stage MEN1-related duodeno-pancreatic NETs.
Materials and methods: Since February 2012, all MEN1 pts with US-endoscopy and/or contrast-enhanced CT/MRI evidence of NETs within duodenum and pancreas (≤10 mm of maximal diameter) were enrolled. Eighteen pts (9 M and 9 F, 20-62 yrs) with NETs of 5.7 mm as average (range, 3-10 mm) were randomized in 2 groups: group A receiving lanreotide autogel 120 mg/28 days, group B without any treatment. All pts were evaluated with US-endoscopy plus CT/MRI every 6 months. At now, there are 6 pts in group A and 12 in group B. Mean follow-up time is 13.4 months (range 6-24).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: DR. Valeria Ramundo
To read results and conclusion, please login ...
Further abstracts you may be interested in